Tech Transfer in the News
JBEI Wiki-based Model is a Successful Technology Commercialization Project
11.02.2010. Thanks to the U. S. Department of Energy's Technology Commercialization Fund and the support of an industry consortium including Boeing, GM and Statoil, researchers at the Joint BioEnergy Institute (JBEI) have created a technoeconomic model that should help accelerate the development of next generation biofuels. This on-line, wiki-based model enables researchers to pursue the most promising strategies for cost-efficient biorefinery operations by simulating such critical factors as production costs and energy balances under different processing scenarios. The goal is to compete successfully with gasoline in terms of economics as well as performance. Read more here.
This technology was also highlighted in the Editor's Choice section of Science (10/22/10).
Berkeley Lab Start-ups Among Wall Street Journal Innovation Award Winners
09.27.2010. Two start-up companies based on Berkeley Lab technologies were recognized in the 10th annual Wall Street Journal Technology Innovation Awards announced Monday.
Solexant, a runner up in the Energy category, has developed an ultra-thin solar cell manufactured in a roll-to-roll process at a significantly lower price per watt than its competitors. This innovation draws from a Berkeley Lab portfolio of nanocrystal solar cell technologies licensed to Solexant in 2008. The well-funded company has already completed a 2-MW pilot line at its San Jose headquarters and will begin building a 100-MW manufacturing plant next year.
The Nanosys QuantumRail™ device, named a runner up in the Semiconductor category, uses an energy-efficient approach to improve the color range, brightness and intensity of LED displays in notebook computers, smart phones and other devices. QuantumRail employs high performance inorganic nanostructures, called quantum dots, originally developed at Berkeley Lab. Nanosys, Inc. licensed the quantum dot portfolio in 2002.
Almost 600 applications from organizations across 30 countries were submitted to the 2010 Wall Street Journal competition. Innovations that broke from industry standards and showed potential to affect future technologies across many fields received the highest ratings.A panel of judges from VC firms, research institutions and private companies ultimately selected 49 technologies as winners and runners up in 17 categories. See here for the complete story and list of winners.
Berkeley Lab Gets Its Own Entrepreneur in Residence
07.26.2010. Science can be a long, slow haul. The road to discovery is usually filled with endless experiments, much trial and error, reformulating of hypotheses, re-experimenting and, sometimes, a very lucky break. Contrast that with venture capitalism, generally a whirlwind of activity, marked with a rush to get a product to market, beat competitors and turn a profit. Can the two work together? Since late last year Jim Matheson, a partner at VC firm Flagship Ventures, has been Berkeley Lab's "entrepreneur in residence." Read more here.
Berkeley Lab Wins Four 2010 R&D 100 Awards
07.08.2010. Four inventions from Berkeley Lab have been recognized with the R&D 100 award for 2010 from R&D Magazine, which recognizes the 100 most significant proven technological advances of the year. The 2010 awardees are:
Read more here.
Scientists Benefit as Much as Students from “Cleantech to Market” Program
|05.14.2010. Launched as a pilot project at Berkeley Lab, the Cleantech to Market program is finishing its first semester as an official class at UC Berkeley’s Haas School of Business, and it’s safe to say the students learned more than they expected on how to take a technology from the laboratory to the marketplace. What was less expected is how much the scientists got out of the program. Read more here.|
Berkeley Lab Licensed Semiconductor Nanocrystals Put to New Use
03.01.2010. Life Technologies Corporation announced early stage results from its single molecule sequencing technology, a technology that promises to deliver targeted genomic sequence with unmatched accuracy and speed. The core sequencing engine is based on the Qdot(R) nanocrystals technology that was developed at Berkeley Lab by Lab Director Paul Alivisatos and colleague at the Materials Sciences Divisions. Read more here.
Berkeley Lab Start-up Artery Therapeutics Collaborates with Roche
02.10.2010. Artery Therapeutics signed a deal with Swiss drug giant Roche to collaborate on the development of ApoA-I peptide mimetics for cardiovascular disease treatment. The ApoA-I peptide mimetics technology was originally developed by Staff Scientist John Bielicki at the Life Sciences Divsion. In 2006, Artery Therapeutics licensed it to develop AT5261, a lead compound for the treatment of atherosclerosis and secondary prevention of cardiovascular events in patients who have suffered a heart attack or stroke. Read more here.
Nearly 20 Percent Bump for Technology Royalties in FY09
01.27.2010. Lab Director Paul Alivisatos recognized Berkeley Lab researchers who have earned royalties through the successful commercialization of their technologies. Out of the Lab’s $3.8 million in licensing income for FY09, an 18 percent increase from the previous year, over $1.2 million went directly to 128 scientists and authors from the Lab. Read more here.